{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:54:00Z","timestamp":1792590840765,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of active Thyroid eye disease (TED). The current study reviews its efficacy in chronic TED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective review, consecutive patients with chronic stable TED (&gt;2 years), who had received \u22653 infusions of teprotumumab were included. All patients had measurements of proptosis, and calculation of the CAS and diplopia scores before and after therapy. Five-point strabismus scores were also calculated. Patients who had imaging within 4 months prior to therapy and 6 weeks post therapy underwent orbital 3D volumetric analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-one patients met the inclusion criteria. The mean (SD) duration of TED was 81 months (56) and the mean (SD) number of infusions received by each patient was 7 (2). Mean (SD) reduction in proptosis for each study orbit was 3.5\u2009mm (0.4) and 3\u2009mm (0.3) for the fellow orbit. The CAS response was 90% for the study orbit and 87% for the fellow orbit. Of the 15 patients who had diplopia at baseline, 67% had a clinically significant response, while 47% had complete resolution following treatment. Following teprotumumab, mean (SD) reduction of muscle tissue was 2011\u2009mm\n                      <jats:sup>3<\/jats:sup>\n                      (1847) in the study orbit and 1620\u2009mm\n                      <jats:sup>3<\/jats:sup>\n                      (1759) in the fellow orbit. The mean (SD) reduction of fat volume was 2101 mm\n                      <jats:sup>3<\/jats:sup>\n                      (1681) in the study orbit and 1370\u2009mm\n                      <jats:sup>3<\/jats:sup>\n                      (1181) in the fellow orbit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Teprotumumab significantly reduces proptosis, inflammation, diplopia, strabismus and orbital soft tissue volume in patients with chronic TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-021-01593-z","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T05:02:54Z","timestamp":1625806974000},"page":"1553-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Teprotumumab for the treatment of chronic thyroid eye disease"],"prefix":"10.1038","volume":"36","author":[{"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Cockerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N. Engl J Med. 2010;362:726\u201338.","journal-title":"N. Engl J Med"},{"key":"1593_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1530\/EJE-11-0548","volume":"165","author":"M Abraham-Nordling","year":"2011","unstructured":"Abraham-Nordling M, Bystr\u00f6m K, T\u00f6rring O, Lantz M, Berg G, Calissendorff J, et al. Incidence of hyperthyroidism in Sweden. Eur. J. Endocrinol. 2011;165:899\u2013905.","journal-title":"Eur. J. Endocrinol."},{"key":"1593_CR3","doi-asserted-by":"crossref","unstructured":"Ugradar S, Rootman DB. Orbital fat expansion in thyroid eye disease is related to age. Eur. J. Ophthalmol. 2020;30.","DOI":"10.1177\/1120672119852322"},{"key":"1593_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/IOP.0000000000001292","volume":"35","author":"S Ugradar","year":"2019","unstructured":"Ugradar S, Goldberg RA, Rootman DB. Bony orbital volume expansion in thyroid eye disease. Ophthal. Plast. Reconstr. Surg. 2019;35:434\u20137.","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"1593_CR5","first-page":"177","volume":"5","author":"FF Rundle","year":"1945","unstructured":"Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy. Clin. Sci. 1945;5:177\u201394.","journal-title":"Clin. Sci."},{"key":"1593_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 2008;158:273\u201385.","journal-title":"Eur. J. Endocrinol."},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ophtha.2007.10.028","volume":"115","author":"EA Bradley","year":"2008","unstructured":"Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL, et al. Orbital radiation for graves ophthalmopathy. A Report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:398\u2013409.","journal-title":"Ophthalmology"},{"key":"1593_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3109\/01676831003668443","volume":"29","author":"L van Steensel","year":"2010","unstructured":"van Steensel L, Dik WA. The orbital fibroblast: a key player and target for therapy in Graves\u2019 ophthalmopathy. Orbit. 2010;29:202\u20136.","journal-title":"Orbit"},{"key":"1593_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/EJE-07-0558","volume":"158","author":"RJ van Geest","year":"2008","unstructured":"van Geest RJ, Sasim IV, Koppeschaar HPF, Kalmann R, Stravers SN, Bijlsma WR, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: A prospective, randomized, placebo-controlled study. Eur. J. Endocrinol. 2008;158:229\u201337.","journal-title":"Eur. J. Endocrinol."},{"key":"1593_CR10","first-page":"110","volume":"3","author":"LD Pasquier-Fediaevsky","year":"2014","unstructured":"Pasquier-Fediaevsky LD, Andrei S, Berche M, Leenhardt L, H\u00e9ron E, Rivi\u00e8re S, et al. Low dose of rituximab for corticosteroid-resistant graves\u2019 orbitopathy. Eur. Thyroid J. 2014;3:110.","journal-title":"Eur. Thyroid J."},{"key":"1593_CR11","doi-asserted-by":"crossref","unstructured":"Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM. Orbital decompression for thyroid eye disease: methods, outcomes, and complications. Eye. 2017. http:\/\/www.nature.com\/doifinder\/10.1038\/eye.2017.260.","DOI":"10.1038\/eye.2017.260"},{"key":"1593_CR12","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J. Immunol. 2008;181:4397\u2013405.","journal-title":"J. Immunol."},{"key":"1593_CR13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1210\/jc.2014-3566","volume":"100","author":"CC Krieger","year":"2015","unstructured":"Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins. J. Clin. Endocrinol. Metab. 2015;100:1071\u20137.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1593_CR14","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N. Immunoglobulins from patients with graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J. Clin. Endocrinol. Metab. 2004;89:5076\u201380.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1593_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1677\/joe.0.1490351","volume":"149","author":"R Kooijman","year":"1996","unstructured":"Kooijman R, Rijkers GT, Zegers BJM. IGF-I potentiates interleukin-2 production in human peripheral T cells. J. Endocrinol. 1996;149:351\u20136.","journal-title":"J. Endocrinol."},{"key":"1593_CR16","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1210\/endo.137.11.8895324","volume":"137","author":"G Renier","year":"1996","unstructured":"Renier G, Cl\u00e9ment I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-\u03b1 production. Endocrinology. 1996;137:4611\u20138.","journal-title":"Endocrinology"},{"key":"1593_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0898-6568(03)00069-X","volume":"15","author":"R Kooijman","year":"2003","unstructured":"Kooijman R, Coppens A, Hooghe-Peters E. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase. Cell. Signal. 2003;15:1091\u20138.","journal-title":"Cell. Signal"},{"key":"1593_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11910-012-0256-9","volume":"12","author":"EF Gillespie","year":"2012","unstructured":"Gillespie EF, Smith TJ, Douglas RS. Thyroid eye disease: towards an evidence base for treatment in the 21st century. Curr. Neurol. Neurosci. Rep. 2012;12:318\u201324.","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1593_CR19","doi-asserted-by":"publisher","unstructured":"Ugradar S, Shi L, Wang Y, Mester T, Yang H, Douglas RS. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye. 2020. https:\/\/doi.org\/10.1038\/s41433-020-01297-w. Online ahead of print.","DOI":"10.1038\/s41433-020-01297-w"},{"key":"1593_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Teprotumumab: first approval. Drugs. 2020;80:509\u201312.","journal-title":"Drugs"},{"key":"1593_CR21","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 2017;376:1748\u201361.","journal-title":"N. Engl. J. Med."},{"key":"1593_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson E, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 2020;382:341\u201352.","journal-title":"N. Engl. J. Med."},{"key":"1593_CR23","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.ajoc.2020.100744","volume":"19","author":"DJ Ozzello","year":"2020","unstructured":"Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am. J. Ophthalmol. Case Rep. 2020;19:100744.","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"1593_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br. J. Ophthalmol. 1989;73:639\u201344.","journal-title":"Br. J. Ophthalmol."},{"key":"1593_CR25","doi-asserted-by":"crossref","unstructured":"Jain AP, Gellada N, Ugradar S, Kumar A, Kahaly G, Douglas R. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br. J. Ophthalmol. 2020.","DOI":"10.1136\/bjophthalmol-2020-317806"},{"key":"1593_CR26","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1167\/iovs.07-1030","volume":"49","author":"NI Regensburg","year":"2008","unstructured":"Regensburg NI, Kok PHB, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM, et al. A new and validated CT-based method for the calculation of orbital Soft tissue volumes. Investig. Ophthalmol. Vis. Sci. 2008;49:1758\u201362.","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"1593_CR27","doi-asserted-by":"publisher","first-page":"e34173","DOI":"10.1371\/journal.pone.0034173","volume":"7","author":"N Hoa","year":"2012","unstructured":"Hoa N, Tsui S, Afifiyan NF, Hikim A, Li B, Douglas RS, et al. Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves\u2019 disease: Apparent role of ADAM17. PLoS One. 2012;7:e34173.","journal-title":"PLoS One"},{"key":"1593_CR28","first-page":"4079","volume":"84","author":"LA Kaback","year":"1999","unstructured":"Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1\u03b2 in human orbital fibroblasts: Potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 1999;84:4079\u201384.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1593_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance of graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 2013;98:145\u201352.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1593_CR30","first-page":"283","volume":"106","author":"KA Ponto","year":"2009","unstructured":"Ponto KA, Pitz S, Pfeiffer N, Hommel G, Weber MM, Kahaly GJ. Quality of life and occupational disability in endocrine orbitopathy. Dtsch. Arztebl. Int. 2009;106:283\u20139.","journal-title":"Dtsch. Arztebl. Int."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01593-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T03:08:09Z","timestamp":1658459289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01593-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01593-z","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RD\u2014Consultant Horizon Therapeutics, Immunovant Corporation, Veridian Corporation. KC\u2014Consultant Horizon Therapeutics, Viridian Pharmaceuticals and 3T Ophthalmics. AH-Consultant Horizon Therapeutics, Osmotica Pharmaceuticals. AK\u2014Consultant Horizon Therapeutics, Osmotica Pharmaceuticals, Immunovant Corporation, Axogen Corporation.\u00a0Horizon Therapeutics funded the publication fees after the article was accepted for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}